Trials / Completed
CompletedNCT04437199
Tricaprilin Phase 2 Pilot Study in Migraine
A 12-Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Participants With Migraine
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Cerecin · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of tricaprilin as AC-SD-03 compared with placebo for the reduction of migraine in participants with frequent migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tricaprilin | Powder formulation will be mixed with 240 mL water and shaken until fully dispersed. Each dosing unit of 12.5 g of AC-SD-03 contains 5 g of the active ingredients (tricaprilin) |
| DRUG | Placebo | Powder formulation will be mixed with 240 mL water and shaken until fully dispersed. |
Timeline
- Start date
- 2020-12-17
- Primary completion
- 2022-02-07
- Completion
- 2022-02-07
- First posted
- 2020-06-18
- Last updated
- 2024-02-08
Locations
10 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT04437199. Inclusion in this directory is not an endorsement.